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Schistosoma mansoni-induced mesangiocapillary glomerulonephritis:
Influence of therapy. Schistosomiasis mansoni has been well docu-
mented as one of the causes of infectious glomerulopathy, with mes-
angiocapillary glomerulonephritis being the most frequent lesion ob-
served in this condition. Twenty-one patients with hepatosplenic
schistosomiasis mansoni and biopsy-documented mesangiocapillary
glomerulonephritis (MCGN) were studied and compared with 19 pa-
tients with the idiopathic form of MCGN. Nephrotic syndrome was the
most frequent clinical presentation in both groups. At the time of
diagnosis nine patients with hepatosplenomegaly (4 with associated
arterial hypertension) and 12 (8 with arterial hypertension) among the
patients with idiopathic MCGN had renal insufficiency. At the end of
the follow-up period 16 patients with hepatosplenic schistosomiasis and
MCGN (75.2 months) and 15 with the idiopathic form (52.1 months) had
renal failure. Also, when compared at 48 months of follow-up, no
difference in renal function could be detected in both groups. No
benefits related to anti-parasitic treatment in the schistosomiasis group
and immunosuppression therapy in either group could be documented.
The progression of the renal disease, as assessed by the reciprocal of
serum creatinine versus time, and the survival curve, were not different
between the two groups. It is concluded that MCGN in patients with the
hepatosplenic form of schistosomiasis mansoni is a progressive disease
not influenced by anti-parasitic or immunosuppressive therapy, and
presents a clinical course similar to that of the idiopathic form.
Mesangiocapillary glomerulonephritis is an important cause
of nephrotic syndrome and chronic renal failure. Although
frequently idiopathic, it is sometimes associated with inherit-
able, systemic or infectious disease [1—3]. The clinical course of
the idiopathic form of mesangiocapillary glomerulonephritis is
characterized by a progression toward advanced renal failure
without being clearly influenced by immunosuppressive therapy
[1, 31. The clinical course and the influence of cure or control of
the underlying disease on the progression of the secondary form
this glomerular disease is unknown.
Schistosomiasis mansoni (S. mansoni) has been well docu-
mented as one of the causes of glomerulopathy [4—10]. Glomer-
ulonephritis has been documented in 15% of the patients with
the hepatosplenic form of this chronic parasitic disease [4, 9].
Although other glomerulopathies have been found, mesangio-
capillary glomerulonephritis is the most frequent glomerular
lesions associated with S. mansoni infection [5, 11]. Even
though an association between glomerulopathy and schistoso-
miasis has been recognized for some time, the course of the
schistosomiasis mansoni-induced mesangiocapillary glomerulo-
nephritis has not been described. The aim of this study was to
analyze the clinical course and the influence of the anti-parasitic
treatment, alone or in combination with immunosuppressive
therapy, in patients with mesangiocapillary glomerulonephritis
and the hepatosplenic form of schistosomiasis mansoni, with
comparisons to the idiopathic form of this glomerulonephritis.
Methods
All patients with biopsy proven diagnosis of mesangiocapil-
lary glomerulonephritis who were seen in the Renal Service of
the Hospital Professor Edgard Santos, Federal University of
Bahia were included in the present study. All patients under-
went percutaneous renal biopsy as part of the evaluation of
renal disease. The specimens were fixed in Bouin's solution,
processed by routine techniques, cut in 2 m thickness and
were stained with hematoxilyn and eosin, PAS, PAS-silver
methanamine and Heidenhein's stain for connective tissue, and
were read by a renal pathologist. The diagnosis of mesangio-
capillary glomerulonephritis was made on the basis of well-
documented histologic criteria [121. In brief, there was involve-
ment of both mesangial area and the peripheral capillary walls;
most frequently the glomeruli were increased in size, with some
accentuation of lobularity. There was mesangial expansion by
cellular proliferation and matrix deposition in some or all the
glomeruli. Division into lobular and non-lobular forms was not
done since a lack of correlation between degree of lobularity
and any clinical feature has been shown [3]. For immunofluo-
rescent studies, renal tissues were frozen, cut into 6 m
sections in a cryostat, and stained with fluorescein-conjugated
goat antisera to human IgG, 1gM, IgA, C3 and fibrin (Hyland
Lab., Costa Mesa, California, USA).
At the time of the initial evaluation a detailed history and
physical examination were obtained. Clinical presentation, ev-
idence of recent streptococcal disease or previous episodes
suggestive of acute glomerulonephritis, or evidence of systemic
or multiple system disease which could be related to nephrotic
syndrome were recorded. Laboratory evaluation included stool
examination, urinalysis, 24-hour urinary protein excretion, Se-
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rum levels of urea nitrogen, creatinine, albumin, cholesterol,
fasting blood sugar and C3. Also, evaluation of the presence of
hepatitis B virus surface antigen was performed in most pa-
tients.
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Schistosomiasis mansoni was diagnosed by the demonstra-
tion of viable eggs of S. mansoni in stools; no quantitative egg
counts were performed. All the patients with schistosomiasis
had, on physical examination, enlarged and firm liver, with an
irregular surface and prominent left lobe. The spleen was also
enlarged in 16 patients. Splenectomy had been previously
performed in five cases. Idiopathic mesangiocapillary glomeru-
lonephritis was considered in the absence of any disease that
could be related to the glomerulopathy.
For the purpose of the present study, nephrotic syndrome
was diagnosed by the presence of edema, urinary protein
excretion greater than 3.5 g/24 hr, serum albumin levels below
3.0 gldl with or without high serum cholesterol levels. Renal
failure was defined by serum creatinine above 1.5 mg/dl and/or
urea nitrogen above 25 mg/dl. End-stage renal failure was
defined by serum creatinine above 10.0 mg/dl or by the need of
dialysis therapy. Arterial hypertension was defined when blood
pressure was over 140/90 mm Hg.
Patients with nephrotic syndrome were treated with immu-
nosuppressive drugs, and with low salt diets, diuretics and
anti-hypertensive medication as needed. Prednisone was ad-
ministered in a dosage of 60 mg/day for four to six weeks,
followed by 60 mg every other day for a month and then
gradually discontinued. If no response to the steroid had
occurred after six weeks of therapy or a steroid dependence
was characterized, cyclophosphamide was added in a dosage of
2 to 3 mg/kg for 8 to 12 weeks, given concommitantly with the
steroid. Hycanthone, used in a dosage of 2 mg/kg single dose,
parenteral or oxamniquine, 15 mg/kg orally single dose, were
used to treat the schistosomiasis. Both drugs are anti-schisto-
somiasis drugs, which have been shown to cure more than 92%
of patients [131.
Remission (spontaneous or induced by therapy) was defined
by the absence (complete) or reduction (partial) of proteinuria
and disappearance of edema. Relapse was defined by the
recurrence of proteinuria after the urine had been free of protein
for at least four weeks. The clinical response to steroid therapy
was designated as follows: steroid responsiveness, defined as a
complete remission during steroid therapy and persistence of
remission for at least six weeks after therapy; steroid depen-
dence, defined as a complete remission during steroid therapy
but recurrence when dosage was reduced or with relapse
occurring within the first month after therapy; and steroid
resistance, no remission during four to six weeks of daily
therapy. The immunosuppressive therapy was well tolerated
and in no instance was it necessary to be discontinued. Besides
mild signs of hypertisolism related to steroids and mild and
transient leukopenia and, in one patient, alopecia, no other
complications related to the therapy were documented.
The clinical course of each patient was evaluated by measur-
ing levels of blood pressure (combined with history of anti-
hypertensive drug use), serum levels of urea nitrogen, creati-
nine, albumin and by the correlation between the reciprocal of
serum creatinine and time (months). The survival rate was
calculated according to Cutler and Ederer [14].
Results
Forty patients were enrolled in the present study. Twenty-
one had the hepatosplenic form of schistosorniasis mansoni and
Table 1. Mesangiocapillary glomerulonephritis: General data and
clinical presentation
HS/S Idiopathic
Sex
Male 15 11
Female 6 8
Total 21 19
Age, mean yr 31.4 0.4 31.2 16.8
range yr 12 to 66 11 to 68
Length of disease 14.0 11.5
nonths
Follow-up months 74.2 52.1
Clinical presentation
Nephrotic syndrome 20 14
Proteinuria 1 4
Acute nephritis 0 1
Total 21 19
19 had no evidence of systemic and/or metabolic disease (Table
1).
Hepatosplenic schistosomiasis patients
Among the 21 patients with S. mansoni infection, 15 were
male and 6 female, with a mean age of 31.4 years (range 12 to 66
years). Nephrotic syndrome was the most frequent clinical
manifestation of MCGN (20 patient); microscopic hematuna
was present in all patients. At the time of the diagnosis of
nephrotic syndrome, hypertension was documented in eight
patients and renal failure was already present in eight patients (4
patients had hypertension and renal failure). Normal serum
cholesterol was documented in nine patients. In one patient the
manifestation of renal disease was asymptomatic proteinuna,
microscopic hematuria and hypertension with normal renal
function. The serum levels of C3 were assessed in 15 patients
(Table 2). These were low in three patients, normal in seven and
variable in five. No correlation was found between activity of
disease and levels of C3. The hepatitis B virus surface antigen
was positive in only one of the 12 patients studied.
The clinical course of these patients is shown in Table 2. At
the end of the observation period (mean of 75.2 months), all the
patients whose manifestation was nephrotic syndrome contin-
ued with proteinuria, which was greater than 3.5 g/24 hr in 13
individuals. There was progression of renal failure in all the
patients who already had renal insufficiency at the time of first
evaluation, and another seven patients developed renal failure.
In nine of these 15 patients the renal failure was advanced,
requiring dialysis therapy. Seven patients developed hyperten-
sion during observation. Of the fifteen patients with hyperten-
sion at the end of the period of observation, twelve developed
renal failure.
Two patients were treated with anti-parasitic drugs, 11 with
anti-parasitic and immunosuppressive drugs, and four with
immunosuppressive drugs alone. All patients were steroid-
resistant and in no patient could a therapeutic response to
immunosuppressive drugs, to anti-parasitic drugs, or to the
combination of immunosuppressive and anti-parasitic drugs,
could be documented. There was no apparent influence of
therapy on renal function (Table 3).
Table 4 shows the influence of renal insufficiency and/or
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Table 2. Hepatosplenic schistosomiasis mansoni and mesangiocapillary glomerulonephritis: Clinical and laboratories data
Therapy No,
Renal function
Normal
Renal
insufficiency
End-stage
renal
disease
Immunosuppressive
Anti-parasitic
Immunosuppressive!
anti-parasitic
No therapy
4
2
11
4
1
1
2
2
1
0
3
2
2
1
6
0
Total 21 6 6 9
hypertension at the time the patient was initially seen, and the
outcome. There was progression or development of renal
failure in most of them, particularly among the patients with
both conditions at the time of diagnosis of nephrotic syndrome.
No correlation was found between levels of C3 and prognosis,
although three patients with persistent hypocomplementemia
developed renal failure. Histologically there was no peculiar
finding related to this group of patients: the glomeruli were
enlarged with some lobular accentuation due to hypercellularity
and splitting of the glomerular basement membrane. The hyper-
cellularity included mesangial and endothelial cells and occa-
Renal function
Renal End-
Patients Normal failure stage
Hypertension
HS/S 5 2 0 3
Idiopathic 6 1 4 1
Renal failure
HS/S 4 0 3 1
Idiopathic 1 0 0 1
Both
HS/S 4 0 0 4
Idiopathic 8 0 4 4
Total 28 3 11 14
None
HS/S 8 4 3 1
Idiopathic 4 3 0 1
sionally mononuclear cells. Only a few sclerotic glomeruli were
seen on the initial renal biopsy. From immunofluorescent
observation granular deposits were seen, consisting predomi-
nantely of 1gM, IgG, C3, and, occasionally, fibrin. No relation-
ship between any specific finding and outcome could be docu-
mented.
The survival rate is presented in Figure 1: 88% at the end of
Age at
onset
Interval
from
onset
Initial studies Final studies
Follow-
upBP BUN Creat Albumin Cholest BP BUN Creat Albumin
Sex yr months mm Hg mg!dl mg/dl g!dt mg!dI Protd Treatmentr mm Hg mg/dl mg/dl g/dl Prot" C3C months
Nephrotic
syndrome
F 30 4 150/80 33 — 2.9 395 3+ Steroid + Cyc 160/100 69 5.9 3.6 2+ N 184
M 33 12 140/90 13 — 1.8 650 4+ Steroid + Cyc" 210/120 106 10.0 3.4 3+ V 156
F 19 20 120/80 13 0.9 1.0 558 4+ Steroid + Cyc' 150/110 27 2.1 5.1 Tr N 151
M
M
27
32
60
1
140/110 37 2.1 2.2
120/80 25 1.1 2.7
345 4+
146 4+
Steroid + Cyc 140/90 200 8.0 2.1
Steroid + Cyc" 120/80 16 0.7 3.8
1+
3+
L
V
132
97
M 40 2 130/80 9 1.2 2.9 214 4+ Steroid + Cyc 200/120 13 0.9 5.3 3+ — 92
M 24 9 130/80 19 1.2 2.9 268 3+ Steroid + Cycb 180/110 41 2.3 2.7 4+ V 84
F 22 60 140/90 12 — 1.9 500 4+ Steroid + Cyc 160/100 164 14.5 3.3 4+ N 77
F
M
66
42
24
5
150/90 30 1.3 2.1
190/120 20 2.0 2.2
214 3+
330 3+
Steroid + CYCb 130/80 14 1.4 4.3
Steroid + Cyc" 170/110 93 11.3 3.2
Tr
1+
N
N
73
72
M 33 16 220/160 22 1.4 1.8 495 4+ Steroid + CYCb 150/100 146 15.6 1.7 3+ L 66
M 29 7 160/110 27 1.3 1.9 555 3+ Steroid + Cyc" 140/100 13 0.8 4.8 2+ V 61
MC 25 1 150/90 33 1.7 2.0 231 4+ Steroid + Cyc" 140/100 156 10.8 3.2 3+ L 57
M
M
36
30
5
20
130/90 15 1.1 2.8
150/90 21 1.4 2.0
208 4+
— 3+
Steroid + Cycb 150/100 102 8.5 2.2
Steroid + Cycb 150/100 33 1.8 —
4+
3+
V
—
52
34
F 25 6 140/80 26 — 1.6 447 4+ Steroid + Cyc 140/100 97 7.5 3.0 4+ — 31
M 23 1 150/100 42 1.5 1.9 167 4+ Steroid + Cycb 140/100 132 11.0 — 3+ — 30
M 27 3 140/80 19 1.0 2.5 284 3+ — 120/80 II 1.1 4.1 2+ — 21
M 31 12 120/80 44 1.9 1.0 254 4+ — 120/80 28 1.6 3.9 1+ — 13
M 19 9 110/80 25 1.9 2.5 3+ — 110/80 43 1.5 4.0 2+ N 12
Proteinuria
F 47 C 170/100 19 0.9 2.1 425 1+ — 150/110 16 1.1 N 86
C Days
b Anti-parasitic treatment
HB5Ag = positived Abbreviations are: Tr, trace; 1+, 10—30 mg/dl; 2+,
Abbreviations are: N, normal; V, variable; L, low.
Abbreviation Cyc is cyclophosphamide
Table 3. Hepatosplenic schistosomiasis mansoni and
mesangiocapillary glomerulonephritis: influence
of therapy on renal function
40—200 mg/dl; 3+, 200—500 mg/dl; 4+, >500 mg/dl.
Table 4. Mesangiocapillary glomerulonephritis: influence of
hypertension and/or renal failure on outcome
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three years, 76% at the end of five years and 57% at the end of
10 years from the first documentation of proteinuria. The mean
interval period between the first documentation of renal failure
and the need for dialysis was 51 months (range 10 to 132
months). The correlation between the reciprocal of serum
creatinine and time is shown in Figure 2 (r = 0.86, y = 0.73 —
0.Olx).
Idiopathic mesangiocapillary glomerulonephritis
Eleven patients were male and eight were female, with a
mean age of 31.2 years (range 11 to 52 years). The clinical
manifestation of the glomerulonephritis were (Table 1) ne-
phrotic syndrome in 14 patients (10 already with renal failure,
and 11 with arterial hypertension). Four patients presented with
asymptomatic proteinuria and normal function (two of them
being hypertensive), and one patient presented with nephritic
features and normal renal function. Five patients had persis-
tently normal serum levels of C3, and two had low levels. No
correlation was found between activity of disease or presence
of HBsAg and complement levels. Hepatitis B virus surface
antigen was positive in three of eight nephrotic patients (Table
5). At light microscopic examination the findings were similar to
that observed in patients with hepatosplenic schistosomiasis,
although, in immunofluorescent studies there was a predomi-
nant deposition of IgG, C3 and 1gM.
At the end of the follow-up at 52.1 months (range 10 to 124
months), all patients still had proteinuria, being in nephrotic
ranges in 10 and intermittent in one patient. Two patients
developed hypertension and three developed renal failure (one
patient had transient renal insufficiency at the time of this
evaluation). The patients with clinical manifestations other than
nephrotic syndrome also presented a progressive course similar
to the patients with nephrotic features.
As in the group of patients with schistosomiasis mansoni,
arterial hypertension and/or renal failure already present at the
first evaluation were associated with a progressive course. No
relationship was found between presence of HBsAg, levels of
C3 and the presence or absence of lobulation in the glomeruli
and clinical course. Regarding the use of immunosuppressive
drugs, nine nephrotic patients were treated, and partial remis-
sion was observed in one patient. No difference was apparent
between the treated and untreated patients. The interval be-
tween the first documentation of renal failure and the progres-
sioll to end-stage renal failure were not different from the
schistosorniasis mansoni groups (P < 0.05 at 42 months). In
addition the survival rate (72% at 3 and 5 years and 37% at 10
years, Fig. 1) and the rate of progression of renal failure (r = 0.76;
y = 0.61 — 0.Olx) did not differ between these groups (Fig. 2).
Except for the finding of hepatosplenomegaly on the physical
examination, the clinical manifestations, course and prognosis
as evaluated by the relationship between reciprocal of serum
creatinine over time and survival rate, were similar in both
groups. In order to rule out the length of follow-up as a selective
factor, both group of patients were analyzed at 48 months with
regard to renal function. No differences could be documented.
Discussion
The association between glomerulonephntis and S. mansoni
is well established on the basis of clinical and laboratory studies
[4-10, 15—17]. Antigenic material from different morphological
stages of S. mansoni has been documented in the serum and
urine of infected animals and humans [7, 8, 16—18]. In addition,
a large molecular weight, negatively-charged proteoglycan,
extractable from the gut of the worm, has been identified in the
glomeruli of infected humans and animals with portal hyperten-
sion [6, 8, 19—231. Furthermore, glomerular lesions similar to
the ones found in humans have been produced in animals
infected with S. mansoni [7, 24]. Even though the search for
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Fig. 1. Survival rate in patients with mesangiocapilla,y glomerulone-
phri:is. Symbols are: (—) hepatosplenic MCGN; (— — — —) idiopathic
MCGN.
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Fig. 2. Reciprocal of serum creatinine with time in patients with
mesangiocapillarv glomerulonephritis. Symbols are: (—)hepatosplen-
ic MCGN, r = 0.8637, y = 0.7289 — 0.116x; and (———--) idiopathic
MCGN, r = 0.7607, y = 0.6105 — 0.168x.
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Table 5. Idiopathic mesangiocapillary glomerulonephritis: Clinical and laboratories data
Interval
Age at from
onset onset
Initial studies Final studies
Follow-
upCholestBP BUN Creat Albumin BP BUN Creat Albumin
Sex yr months mm Hg mg/d! mg/dl gid! mg/dI Prota Treatment mm Hg mg/d! mg/dI g/dl ProtC C3f months
Nephrotic syndrome
MC 17 24 140/70 1.5 2.6 172 4+ Steroid + Cyc 120/80 16 1.2 4.0 1+ N 124
F 25 5 180/140 17 1.3 3.0 234 3+ — 120/110 18 1.1 3.6 3+ N 123
F 13 10 150/100 21 2.1 1.7 477 4+ Steroid + Cyc 1701120 67 10.0 2.6 1+ 118
M 23 10
M 12 b
140/80 15 1.5 2.2
130/80 18 2.8 1.4
217 3+
338 4+
Steroid + Cyc 130/90 188 10.0 2.7
Steroid + Cyc 140/100 76 5.6 2.9
3+
4+
73
57
FC 60 2 200/120 28 1.7 3.0 326 3+ — 180/90 43 3.2 4.0 1+ L 48
F 19 24 180/120 26 1.8 2.5 286 3+ — 140/100 44 3.5 3.2 4+ N 46
M 45 4 200/100 9 1.0 2.9 4+ Steroid 160/100 34 1.7 2+ 41
F 68 3 210/130 19 1.5 1.9 400 3+ — 200/100 43 4.0 2.4 3+ 36
M 37 12 140/100 27 2.2 1.3 201 4+ Steroid + Cyc 150/100 46 1.9 2.7 4+ 29M' 39 6 170/110 32 3.8 2.4 400 4+ Steroid + Cyc 180/100 124 10.0 1.4 3+ 29
M 28 5 150/100 49 1.8 1.7 374 4+ Steroid + Cyc 160/120 138 10.0 3+ N 18M 11 5 150/120 20 2.8 1.8 228 3+ Steroid + Cyc 130/90 48 3.0 2.0 4+ 17M 52 6 160/110 34 1.8 1.8 173 4+ — 140/90 149 10.0 2.2 3+ 10
Abnormalities of urinalysis
31 9 140/100 13 0.8 4.3 204 1+ — 160/110 14.0 4.8 1+ N 34
F 52 60 150/120 17 1.0 3.3 313 2+ — 180/110 23 2.5 2.6 4+ 53
F 21 b 180/120 16 1.1 5.4 237 3+ — 140/110 129 15.0 3.8 3+ L 24
F 30 b 105/80 18 2+ — 120/80 13 1.0 3.8 3+ 73
M Ii 12 110/60 14 4.1 220 3+ Steroid + Cyc 110/60 14 3.4 38
a Patient with nephritic features
' Days
C HBsAg positived Cyc, cyclophosphamide
Proteinuria: 1+, 10—30 mg/dl; 2+, 40—200 mg/dl; 3+, 200—500 mg/dl; 4+, >500/dl.
L, low; N, normal.
deposition of parasitic antigen in the glomeruli of the hepato-
splenic S. mansoni infected patients was not performed, in this
study, there are several points which suggest a specific form of
glomerular disease in such cases [5, 6, 10]. All of them came
from an area endemic for S. mansoni, had documented parasitic
infection and exhibited a severe form of this disease. No
previous history of nephropathy and no other possible associ-
ated condition was documented in any of the cases. Identifica-
tion of antigen in glomeruli is difficult, not only because it is
present in small amounts but also because it could be masked
by immunoglobulin and complement [26]. In addition, a gradual
decline and disappearance over time of these antigens in the
glomeruli of chronically infected animals and humans have been
shown [8, 25].
In the patients studied, except for the findings of hepato-
splenomegaly on physical examination directly related to the S.
mansoni, no other difference, either clinical or histological
could be found between the groups. Nephrotic syndrome was
the most frequent clinical presentation of the mesangiocapillary
glomerulonephritis in both groups of patients. Although renal
failure present at time of the first evaluation was more common
among the patients with the idiopathic form of glomerulonephri-
tis, it was not considered to be a peculiar finding of these
patients. The clinical course of the disease was also similar and
progressive in both groups. Such progression was more rapid
among the patients who presented with renal insufficiency and!
or hypertension. The renal failure suggests a more advanced
glomerular lesion, and the aggravation role hypertension in the
course of glomerular disease is well known.
The rate of progression of the renal failure, as assessed by the
relationship between the reciprocal of serum creatinine and
time, was also similar in both groups. Although not all patients
with renal failure presented a linear decline of renal function, it
seems to be a reliable method for the evaluation of progression
of renal failure. In our series, at time of the final evaluation 70%
of the patients in each group had developed renal failure. Also,
no difference in relation to renal function could be documented
when the patients were evaluated and compared at 48 months of
follow-up. Considering the survival rate, even though it seemed
to be higher among the patients with schistosomiasis mansoni
at three years, it was not statistically different, and tended to be
very similar at five and 10 years, and not different from the
survival of nephrotic patients as documented by others [1—3,
27—29].
The importance of serum levels of C3 in the clinical detection
of glomerulopathy in patients with hepatosplenic schistosomi-
asis has been reported [30, 31]. In the present study, however,
we could not document any relationship between the levels of
complement and the clinical course or prognosis of the disease.
The three patients with persistent hypocomplementemia devel-
oped end-stage renal failure during the follow-up period, but the
number of patients with this finding is small and does not permit
any conclusion. The lack of correlation between complement
levels and course and prognosis of the mesangiocapillary gb-
merulonephritis was also observed in patients with the idio-
pathic form, as has already been reported [3]. Also there was a
lack of a characteristic finding on the histological light micros-
copy studies of the renal biopsies of the S. mansoni group of
patients.
As in the group of patients with the idiopathic form of
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mesangiocapillary glomerulonephritis, the use of immunosup-
pressive drugs did not influence the course of the disease in
patients with schistosomiasis mansoni. Persistent disappear-
ance of proteinuria or influence in the outcome of renal func-
tion, as reported in other forms of glomerular disease, could not
be documented. Except for uncontrolled studies [32, 33], unre-
sponsiveness to immunosuppressive therapy has been found in
most studies of patients with mesangiocapillary glomerulone-
phritis [1, 3]. Also, no benefit could be documented by using
anti-parasitic drugs, alone or in association with immunosup-
pressive therapy, despite the cure of the parasitic infection.
Additionally, no detrimental effect related to the parasitic
therapy was apparent [34]. Experimental studies have shown
the importance of the length of infection at the time of anti-
parasitic treatment on the renal disease. Sadum et al [35] while
studying the influence of anti-parasitic therapy on the evolution
of schistosomiasis in chimpanzees, documented that treatment
early in course of the infection prevented or halted the renal
lesions, as compared with untreated or late-treated animals.
Valadares and Pereira [36] also documented the disappearance
of urinalysis abnormalities only in mice treated in the first week
after S. mansoni infection.
Our data suggest that mesangiocapillary glomerulonephritis
in patients with hepatosplenic form of S. mansoni infection is a
progressive disease, and shows a clinical course similar to that
of the idiopathic form. Once the glomerulopathy is already
established and clinically manifested, it seems to progress to an
advanced stage, where the hemodynamic adaptations that fol-
low reduction of functional renal mass are already present [37]
independently of the presence or absence of the parasite. This
emphasizes the importance of early diagnosis and therapy of the
S. mansoni infection.
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